Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. trimmed its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 29.0% during the second quarter, Holdings Channel reports. The firm owned 7,868 shares of the company’s stock after selling 3,214 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Recursion Pharmaceuticals were worth $59,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Mubadala Investment Co PJSC acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth about $128,041,000. ARK Investment Management LLC increased its stake in Recursion Pharmaceuticals by 14.5% during the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after purchasing an additional 3,555,357 shares during the period. Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $34,825,000. Baillie Gifford & Co. boosted its stake in shares of Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after purchasing an additional 2,522,132 shares during the period. Finally, Kinnevik AB publ grew its holdings in shares of Recursion Pharmaceuticals by 14.4% in the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock valued at $89,293,000 after purchasing an additional 1,500,000 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $6.76 on Wednesday. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The firm has a market capitalization of $1.90 billion, a PE ratio of -4.22 and a beta of 0.82. The business’s fifty day moving average price is $7.20 and its 200 day moving average price is $8.43.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company’s revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.38) EPS. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of research reports. Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC cut their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Finally, KeyCorp reduced their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.40.

Insider Transactions at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 6,000 shares of the stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $3,860,644.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares in the company, valued at $3,860,644.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total value of $108,860.97. Following the sale, the director now owns 7,177,116 shares in the company, valued at approximately $68,254,373.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 231,682 shares of company stock worth $1,663,867. 15.75% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.